BioAegis Therapeutics Awarded $20 Million BARDA DRIVe

Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for...

Related Keywords

Steven Cordovano ,Christine Lagana ,Susan Levinson ,Division Of Research ,Us Department Of Health ,Bioaegis Therapeutics Inc ,Development Authority ,Administration For Strategic Preparedness ,Biomedical Advanced Research ,Society Vulnerability To Global Pandemics ,Human Services ,Aegis Therapeutics ,Strategic Preparedness ,Acute Respiratory Distress Syndrome ,Reduce Society ,Respiratory Distress Syndrome ,Multitasking Protein ,Complex Condition ,Chief Executive Officer ,Bioaegis Therapeutics ,Cards ,Pneumonia ,Sepsis ,Lrp3 Inflammasome ,Inflammation ,Harda ,Innate Immune System ,Elsolin ,Biotech Investing ,Mr ,Immunotherapy ,L 1b ,